Search

Your search keyword '"Fuchs, Ephraim"' showing total 872 results
Start Over Author "Fuchs, Ephraim"
872 results on '"Fuchs, Ephraim"'

1. TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers

Author

Nichakawade, Tushar D., Ge, Jiaxin, Mog, Brian J., Lee, Bum Seok, Pearlman, Alexander H., Hwang, Michael S., DiNapoli, Sarah R., Wyhs, Nicolas, Marcou, Nikita, Glavaris, Stephanie, Konig, Maximilian F., Gabelli, Sandra B., Watson, Evangeline, Sterling, Cole, Wagner-Johnston, Nina, Rozati, Sima, Swinnen, Lode, Fuchs, Ephraim, Pardoll, Drew M., Gabrielson, Kathy, Papadopoulos, Nickolas, Bettegowda, Chetan, Kinzler, Kenneth W., Zhou, Shibin, Sur, Surojit, Vogelstein, Bert, and Paul, Suman

Published
2024
Full Text
View/download PDF

2. Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis and haploidentical stem cell transplantation

Author

Mulroney, Carolyn M, Abid, Muhammad Bilal, Bashey, Asad, Chemaly, Roy F, Ciurea, Stefan O, Chen, Min, Dandoy, Christopher E, Perez, Miguel A Diaz, Friend, Brian D, Fuchs, Ephraim, Ganguly, Siddhartha, Goldsmith, Scott R, Kanakry, Christopher G, Kim, Soyoung, Komanduri, Krishna V, Krem, Maxwell M, Lazarus, Hillard M, Ljungman, Per, Maziarz, Richard, Nishihori, Taiga, Patel, Sagar S, Perales, Miguel‐Angel, Romee, Rizwan, Singh, Anurag K, Wingard, John Reid, Yared, Jean, Riches, Marcie, and Taplitz, Randy

Subjects
Prevention, Transplantation, Lung, Stem Cell Research - Nonembryonic - Human, Stem Cell Research, Hematology, Rare Diseases, Organ Transplantation, Orphan Drug, Cancer, Infection, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Community-Acquired Infections, Cyclophosphamide, Female, Graft vs Host Disease, HLA Antigens, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Incidence, Kaplan-Meier Estimate, Leukemia, Living Donors, Male, Middle Aged, Myelodysplastic Syndromes, Proportional Hazards Models, Respiratory Tract Infections, Retrospective Studies, Siblings, Transplantation, Haploidentical, Virus Diseases, Young Adult, Respiratory viral infection, Post Transplant Cyclophosphamide, Allogeneic transplant, Cardiorespiratory Medicine and Haematology, Immunology
Abstract

Community respiratory viral infections (CRVIs) are associated with pulmonary function impairment, alloimmune lung syndromes and inferior survival in human leucocyte antigen (HLA)-matched allogeneic haematopoietic stem cell transplant (HCT) recipients. Although the incidence of viral infections in HLA-haploidentical HCT recipients who receive post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis is reportedly increased, there are insufficient data describing the incidence of CRVIs and the impact of donor source and PTCy on transplant outcomes. Analysing patients receiving their first HCT between 2012 and 2017 for acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndromes, we describe comparative outcomes between matched sibling transplants receiving either calcineurin-based GVHD prophylaxis (SibCNI, N = 1605) or PTCy (SibCy, N = 403), and related haploidentical transplants receiving PTCy (HaploCy, N = 757). The incidence of CRVIs was higher for patients receiving PTCy, regardless of donor type. Patients in the HaploCy cohort who developed a CRVI by day +180 had both a higher risk of treatment-related mortality [hazard ratio (HR) 2⋅14, 99% confidence interval (CI) 1⋅13-4⋅07; P = 0⋅002] and inferior 2-year overall survival (HR 1⋅65, 99% CI 1⋅11-2⋅43; P = 0⋅001) compared to SibCNI with no CRVI. This finding justifies further research into long-term antiviral immune recovery, as well as development of preventive and treatment strategies to improve long-term outcomes in such patients.

Published
2021

3. Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant

Author

Solomon, Scott R, Martin, Andrew St, Zhang, Mei-Jie, Ballen, Karen, Bashey, Asad, Battiwalla, Minoo, Baxter-Lowe, Lee Ann, Brunstein, Claudio, Chhabra, Saurabh, Perez, Miguel Angel Diaz, Fuchs, Ephraim J, Ganguly, Siddhartha, Hardy, Nancy, Hematti, Peiman, McGuirk, Joseph, Peres, Edward, Ringden, Olle, Rizzieri, David, Romee, Rizwan, Solh, Melhem, Szwajcer, David, van der Poel, Marjolein, Waller, Edmund, William, Basem M, and Eapen, Mary

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Stem Cell Research, Stem Cell Research - Nonembryonic - Human, Clinical Research, Transplantation, Hematology, Stem Cell Research - Umbilical Cord Blood/ Placenta - Human, Rare Diseases, Cancer, Regenerative Medicine, Stem Cell Research - Umbilical Cord Blood/ Placenta, Good Health and Well Being, Black or African American, Cord Blood Stem Cell Transplantation, Fetal Blood, Graft vs Host Disease, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Histocompatibility Testing, Humans, Alternative donor, African American, Caucasian, race, leukemia, transplant-related mortality, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

Although hematopoietic cell transplantation from an HLA-matched unrelated donor is potentially curative for hematologic malignancies, survival is lower for African Americans compared with Caucasians. Because only approximately 20% of African Americans will have an HLA-matched unrelated donor, many of these patients undergo HLA-haploidentical relative or umbilical cord blood transplantation. In this study, we analyzed outcomes after HLA-haploidentical related donor (n = 249) and umbilical cord blood (n = 118) transplantations in African American patients with hematologic malignancy between 2008 and 2016. The predominant disease was acute myelogenous leukemia for recipients of both types of donor grafts. The incidences of grade II-IV and III-IV acute graft-versus-host disease were higher after umbilical cord blood transplantation compared with HLA-haploidentical relative transplantation (56% and 29%, respectively, versus 33% and 11%, respectively; P < .0001). The 2-year incidence of transplantation-related mortality adjusted for age and conditioning regimen intensity was higher after umbilical cord blood transplantation compared with HLA-haploidentical related donor transplantation (31% versus 18%; P = .008); however, there were no between-group differences in the 2-year adjusted incidence of relapse (30% versus 34%; P = .51), overall survival (54% versus 57%; P = .66), or disease-free survival (43% versus 47%; P = .46). Our findings show that the use of HLA-haploidentical and umbilical cord blood transplants expands the access to transplantation with comparable leukemia-free and overall survival for African Americans with hematologic malignancies.

Published
2020

5. Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group

Author

Ai, Huisheng, Chao, Nelson J., Rizzieri, David A., Huang, Xiaojun, Spitzer, Thomas R., Wang, Jianxiang, Guo, Mei, Keating, Armand, Krakow, Elizabeth F., Blaise, Didier, Ma, Jun, Wu, Depei, Reagan, John, Gergis, Usama, Duarte, Rafael F., Chaudhary, Preet M., Hu, Kaixun, Yu, Changlin, Sun, Qiyun, Fuchs, Ephraim, Cai, Bo, Huang, Yajing, Qiao, Jianhui, Gottlieb, David, Schultz, Kirk R., Liu, Mingyao, Chen, Xiequn, Chen, Wenming, Wang, Jianmin, Zhang, Xiaohui, Li, Jianyong, Huang, He, Sun, Zimin, Li, Fei, Yang, Linhua, Zhang, Liansheng, Li, Lijuan, Liu, Kaiyan, Jin, Jie, Liu, Qifa, Liu, Daihong, Gao, Chunji, Fan, Chuanbo, Wei, Li, Zhang, Xi, Hu, Liangding, Zhang, Weijing, Tian, Yuyang, Han, Weidong, Zhu, Jun, Xiao, Zhijian, Zhou, Daobin, Zhang, Bolong, Jia, Yongqian, Zhang, Yongqing, Wu, Xiaoxiong, Shen, Xuliang, Lu, Xuzhang, Zhan, Xinrong, Sun, Xiuli, Xiao, Yi, Wang, Jingbo, Shi, Xiaodong, Zheng, Bo, Chen, Jieping, Ding, Banghe, Wang, Zhao, Zhou, Fan, Zhang, Mei, Zhang, Yizhuo, Sun, Jie, Xia, Bing, Chen, Baoan, and Ma, Liangming

Published
2023
Full Text
View/download PDF

6. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT

Author

Dholaria, Bhagirathbhai, Savani, Bipin N, Labopin, Myriam, Luznik, Leo, Ruggeri, Annalisa, Mielke, Stephan, Malki, Monzr M Al, Kongtim, Piyanuch, Fuchs, Ephraim, Huang, Xiao-Jun, Locatelli, Franco, Aversa, Franco, Castagna, Luca, Bacigalupo, Andrea, Martelli, Massimo, Blaise, Didier, Soussan, Patrick Ben, Arnault, Yolande, Handgretinger, Rupert, Roy, Denis-Claude, O’Donnell, Paul, Bashey, Asad, Solomon, Scott, Romee, Rizwan, Lewalle, Philippe, Gayoso, Jorge, Maschan, Michael, Lazarus, Hillard M, Ballen, Karen, Giebel, Sebastian, Baron, Frederic, Ciceri, Fabio, Esteve, Jordi, Gorin, Norbert-Claude, Spyridonidis, Alexandros, Schmid, Christoph, Ciurea, Stefan O, Nagler, Arnon, and Mohty, Mohamad

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Transplantation, Cancer, Regenerative Medicine, Rare Diseases, Prevention, Hematology, Stem Cell Research, Inflammatory and immune system, Consensus, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Lymphocytes, Prospective Studies, Retrospective Studies, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematologic relapse, being able to induce durable remissions in a subset of patients. With the increased use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize the available evidence on the use of donor lymphocyte infusion from haploidentical donor, and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice.

Published
2020

7. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.

Author

Solomon, Scott, St Martin, Andrew, Shah, Nirav, Fatobene, Giancarlo, Al Malki, Monzr, Ballen, Karen, Bashey, Asad, Bejanyan, Nelli, Bolaños Meade, Javier, Brunstein, Claudio, DeFilipp, Zachariah, Champlin, Richard, Fuchs, Ephraim, Hamadani, Mehdi, Hematti, Peiman, Kanakry, Christopher, McGuirk, Joseph, McNiece, Ian, Ciurea, Stefan, Pasquini, Marcelo, Rocha, Vanderson, Romee, Rizwan, Patel, Sagar, Vasu, Sumithira, Waller, Edmund, Wingard, John, Zhang, Mei-Jie, and Eapen, Mary

Subjects
Adolescent, Adult, Disease-Free Survival, Female, Hematologic Neoplasms, Humans, Middle Aged, Myeloablative Agonists, Transplantation Conditioning, Transplantation, Haploidentical, Young Adult
Abstract

In the absence of prospective studies that examine the effect of conditioning regimen intensity after T-cell-replete haploidentical transplant for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS), a retrospective cohort analysis was performed. Of the 1325 eligible patients (AML, n = 818; ALL, n = 286; and MDS, n = 221), 526 patients received a myeloablative regimen and 799 received a reduced-intensity regimen. Graft-versus-host disease prophylaxis was uniform with posttransplant cyclophosphamide, a calcineurin inhibitor, and mycophenolate mofetil. The primary end point was disease-free survival. Cox regression models were built to study the effect of conditioning regimen intensity on transplant outcomes. For patients aged 18 to 54 years, disease-free survival was lower (hazard ratio [HR], 1.34; 42% vs 51%; P = .007) and relapse was higher (HR, 1.51; 44% vs 33%; P = .001) with a reduced-intensity regimen compared with a myeloablative regimen. Nonrelapse mortality did not differ according to regimen intensity. For patients aged 55 to 70 years, disease-free survival (HR, 0.97; 37% vs 43%; P = .83) and relapse (HR, 1.32; 42% vs 31%; P = .11) did not differ according to regimen intensity. Nonrelapse mortality was lower with reduced-intensity regimens (HR, 0.64; 20% vs 31%; P = .02). Myeloablative regimens are preferred for AML, ALL, and MDS; reduced-intensity regimens should be reserved for those unable to tolerate myeloablation.

Published
2019

8. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.

Author

Dreger, Peter, Sureda, Anna, Ahn, Kwang, Eapen, Mary, Litovich, Carlos, Finel, Herve, Boumendil, Ariane, Gopal, Ajay, Herrera, Alex, Schmid, Christoph, Diez-Martin, José, Fuchs, Ephraim, Bolaños-Meade, Javier, Gooptu, Mahasweta, Al Malki, Monzr, Castagna, Luca, Ciurea, Stefan, Dominietto, Alida, Blaise, Didier, Ciceri, Fabio, Tischer, Johanna, Corradini, Paolo, Montoto, Silvia, Robinson, Stephen, Gülbas, Zafer, and Hamadani, Mehdi

Subjects
Adult, Aged, Female, Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Retrospective Studies, Tissue Donors, Transplantation Conditioning, Young Adult
Abstract

This study retrospectively compared long-term outcomes of nonmyeloablative/reduced intensity conditioning (NMC/RIC) allogeneic hematopoietic cell transplantation (allo-HCT) from a haploidentical family donor (haplo-HCT) using posttransplant cyclophosphamide (PTCy) with those of matched sibling donor (MSD) and matched unrelated donor (MUD) with or without T-cell depletion (TCD+/TCD-) in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Adult patients with DLBCL who had undergone their first NMC/RIC allo-HCT between 2008 and 2015 were included. Recipients of haplo-HCT were limited to those receiving graft-versus-host disease (GVHD) prophylaxis with PTCy. GVHD prophylaxis in MSD was limited to calcineurin inhibitor (CNI)-based approaches without in vivo TCD, while MUD recipients received CNI-based prophylaxis with or without TCD. Outcome analyses for overall survival (OS) and progression-free survival (PFS), nonrelapse mortality (NRM), and disease relapse/progression were calculated. A total of 1438 patients (haplo, 132; MSD, 525; MUD TCD+, 403; and MUD TCD-, 378) were included. Patients with haplo donors were significantly older, had a better performance status and had more frequently received total body irradiation-based conditioning regimens and bone marrow grafts than MSD and MUD TCD+ or TCD-. 3-year OS, PFS, NRM and relapse/progression incidence after haplo-HCT was 46%, 38%, 22%, and 41%, respectively, and not significantly different from outcomes of matched donor transplants on multivariate analyses. Haplo-HCT was associated with a lower cumulative incidence of chronic GVHD compared with MSD, MUD TCD+/TCD-. NMC/RIC haplo-HCT with PTCy seems to be a valuable alternative for patients with DLBCL considered for allo-HCT but lacking a matched donor.

Published
2019

9. Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience

Author

Ambinder, Alexander, Smith, Matthew, Tsai, Hua-Ling, Varadhan, Ravi, DeZern, Amy, Dalton, William, Gocke, Christian, Webster, Jonathan, Gondek, Lukasz, Gojo, Ivana, Ali, Syed Abbas, Huff, Carol Ann, Swinnen, Lode, Wagner-Johnston, Nina, Showel, Margaret, Prince, Gabrielle, Borrello, Ivan, Bolaños-Meade, Javier, Luznik, Leo, Jain, Tania, Imus, Philip, Fuchs, Ephraim, Ambinder, Richard, Gladstone, Douglas E., Levis, Mark, Jones, Richard, Ghiaur, Gabriel, and Smith, B. Douglas

Published
2022
Full Text
View/download PDF

10. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

Author

Fuchs, Ephraim J., McCurdy, Shannon R., Solomon, Scott R., Wang, Tao, Herr, Megan R., Modi, Dipenkumar, Grunwald, Michael R., Nishihori, Taiga, Kuxhausen, Michelle, Fingerson, Stephanie, McKallor, Caroline, Bashey, Asad, Kasamon, Yvette L., Bolon, Yung-Tsi, Saad, Ayman, McGuirk, Joseph, Paczesny, Sophie, Gadalla, Shahinaz M., Marsh, Steven G.E., Shaw, Bronwen E., Spellman, Stephen R., Lee, Stephanie J., and Petersdorf, Effie W.

Published
2022
Full Text
View/download PDF

11. Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?

Author

Robinson, Tara, Fuchs, Ephraim, Zhang, Mei-Jie, St Martin, Andrew, Labopin, Myriam, Keesler, Daniel, Blaise, Didier, Bashey, Asad, Bourhis, Jean-Henri, Ciceri, Fabio, Ciurea, Stefan, Devine, Steven, Mohty, Mohamad, McCurdy, Shannon, Milpied, Noel, McNiece, Ian, Rocha, Vanderson, Romee, Rizwan, Socie, Gerard, Yakoub-Agha, Ibrahim, Soiffer, Robert, Eapen, Mary, and Nagler, Arnon

Subjects
Acute Disease, Adolescent, Adult, Aged, Chronic Disease, Cyclophosphamide, Disease-Free Survival, Female, Graft vs Host Disease, HLA Antigens, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Male, Middle Aged, Survival Rate, Tissue Donors
Abstract

We sought to identify whether posttransplantation cyclophosphamide (PT-Cy) reduces or eliminates the detrimental impact of HLA mismatching on outcomes of HLA-haploidentical related donor transplantation for acute leukemia. Data from 2143 donor-recipient pairs (n = 218 haploidentical sibling; n = 218 offspring; n = 1707 HLA-matched sibling) with acute myeloid or lymphoblastic leukemia were studied. All received a calcineurin inhibitor for graft-versus-host disease (GVHD) prophylaxis while high-dose PT-Cy was also given to recipients of haploidentical transplant. Patient age correlated with donor-recipient relationship: haploidentical siblings donated to patients aged 18 to 54 years whereas offspring donated to patients aged 55 to 76 years. Therefore, transplant outcomes were examined separately in the 2 patient age groups. In patients aged 18 to 54 years, there were no significant differences in outcomes except chronic GVHD, which was lower after haploidentical sibling compared to HLA-matched sibling transplant (hazard ratio [HR], 0.63; P < .001). In patients aged 55 to 76 years, despite lower chronic GVHD (HR, 0.42; P < .001), graft failure (14% vs 6%; P = .003), nonrelapse mortality (HR, 1.48; P = .02), and overall mortality (HR, 1.32; P = .003) were higher after transplant from offspring compared with an HLA-matched sibling. These data demonstrate a superior outcome in older recipients when using an HLA-matched sibling instead of offspring, although there were differences in transplant platforms (GVHD prophylaxis and graft type) between the 2 groups. Validation of these findings requires a prospective randomized trial wherein the transplant platforms can be closely matched.

Published
2018

12. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation

Author

Ciurea, Stefan O, Cao, Kai, Fernandez-Vina, Marcelo, Kongtim, Piyanuch, Malki, Monzr Al, Fuchs, Ephraim, Luznik, Leo, Huang, Xiao-Jun, Ciceri, Fabio, Locatelli, Franco, Aversa, Franco, Castagna, Luca, Bacigalupo, Andrea, Martelli, Massimo, Blaise, Didier, Handgretinger, Rupert, Roy, Denis-Claude, O’Donnell, Paul, Bashey, Asad, Lazarus, Hillard M, Ballen, Karen, Savani, Bipin N, Mohty, Mohamad, and Nagler, Arnon

Subjects
Transplantation, Regenerative Medicine, Stem Cell Research, Organ Transplantation, Development of treatments and therapeutic interventions, 5.4 Surgery, Inflammatory and immune system, Bone Marrow Transplantation, Graft Rejection, HLA Antigens, Hematopoietic Stem Cell Transplantation, Humans, Isoantibodies, Tissue Donors, Transplantation, Haploidentical, Treatment Outcome, Clinical Sciences, Oncology and Carcinogenesis, Immunology
Abstract

Haploidentical donors are now increasingly considered for transplantation in the absence of HLA-matched donors or when an urgent transplant is needed. Donor-specific anti-HLA antibodies (DSA) have been recently recognized as an important barrier against successful engraftment of donor cells, which can affect transplant survival. DSA appear more prevalent in this type of transplant due to higher likelihood of alloimmunization of multiparous females against offspring's HLA antigens, and the degree of mismatch. Here we summarize the evidence for the role of DSA in the development of primary graft failure in haploidentical transplantation and provide consensus recommendations from the European Society for Blood and Marrow Transplant Group on testing, monitoring, and treatment of patients with DSA receiving haploidentical hematopoietic progenitor cell transplantation.

Published
2018

13. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016

Author

Malki, Monzr M Al, Jones, Richard, Ma, Qing, Lee, Dean, Reisner, Yair, Miller, Jeffrey S, Lang, Peter, Hongeng, Suradej, Hari, Parameswaran, Strober, Samuel, Yu, Jianhua, Maziarz, Richard, Mavilio, Domenico, Roy, Denis-Claude, Bonini, Chiara, Champlin, Richard E, Fuchs, Ephraim J, and Ciurea, Stefan O

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Stem Cell Research - Nonembryonic - Human, Regenerative Medicine, Hematology, Stem Cell Research, Organ Transplantation, Transplantation, Rare Diseases, Good Health and Well Being, California, Cell- and Tissue-Based Therapy, Congresses as Topic, Hemoglobinopathies, Humans, Immunotherapy, Leukocyte Reduction Procedures, Neoplasms, Stem Cell Transplantation, Transplantation, Haploidentical, Cellular therapy, Haploidentical transplantation, Immunologic reconstitution, Post-transplantation cyclophosphamide, T cell depletion, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

The resurgence of haploidentical stem cell transplantation (HaploSCT) over the last decade is one of the most important advances in the field of hematopoietic stem cell transplantation (HSCT). The modified platforms of T cell depletion either ex vivo (CD34+ cell selection, "megadoses" of purified CD34+ cells, or selective depletion of T cells) or newer platforms of in vivo depletion of T cells, with either post-transplantation high-dose cyclophosphamide or intensified immune suppression, have contributed to better outcomes, with survival similar to that in HLA-matched donor transplantation. Further efforts are underway to control viral reactivation using modified T cells, improve immunologic reconstitution, and decrease the relapse rate post-transplantation using donor-derived cellular therapy products, such as genetically modified donor lymphocytes and natural killer cells. Improvements in treatment-related mortality have allowed the extension of haploidentical donor transplants to patients with hemoglobinopathies, such as thalassemia and sickle cell disease, and the possible development of platforms for immunotherapy in solid tumors. Moreover, combining HSCT from a related donor with solid organ transplantation could allow early tapering of immunosuppression in recipients of solid organ transplants and hopefully prevent organ rejection in this setting. This symposium summarizes some of the most important recent advances in HaploSCT and provides a glimpse in the future of fast growing field.

Published
2018

16. Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

Author

Imus, Philip H., Tsai, Hua-Ling, DeZern, Amy E., Jerde, Kevin, Swinnen, Lode J., Bolaños-Meade, Javier, Luznik, Leo, Fuchs, Ephraim J., Wagner-Johnston, Nina, Huff, Carol Ann, Gladstone, Douglas E., Ambinder, Richard F., Gocke, Christian B., Ali, Syed Abbas, Borrello, Ivan M., Varadhan, Ravi, Brodsky, Robert, and Jones, Richard J.

Published
2020
Full Text
View/download PDF

17. Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide

Author

DeZern, Amy E., Elmariah, Hany, Zahurak, Marianna, Rosner, Gary L., Gladstone, Douglas E., Ali, Syed Abbas, Huff, Carol Ann, Swinnen, Lode J., Imus, Phil, Borrello, Ivan, Wagner-Johnston, Nina D., Ambinder, Richard F., Brodsky, Robert A., Cooke, Kenneth, Luznik, Leo, Fuchs, Ephraim J., Bolaños-Meade, Javier, and Jones, Richard J.

Published
2020
Full Text
View/download PDF

18. Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide

Author

Webster, Jonathan A., Luznik, Leo, Tsai, Hua-Ling, Imus, Philip H., DeZern, Amy E., Pratz, Keith W., Levis, Mark J., Gojo, Ivana, Showel, Margaret M., Prince, Gabrielle, Bolaños-Meade, Javier, Gondek, Lukasz P., Ghiaur, Gabriel, Dalton, W. Brian, Jain, Tania, Fuchs, Ephraim J., Gladstone, Douglas E., Gocke, Christian B., Ali, Syed Abbas, Huff, Carol Ann, Borrello, Ivan M., Swinnen, Lode, Wagner-Johnston, Nina, Ambinder, Richard F., Jones, Richard J., and Smith, B. Douglas

Published
2020
Full Text
View/download PDF

19. Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant

Author

Solomon, Scott R., Martin, Andrew St, Zhang, Mei-Jie, Ballen, Karen, Bashey, Asad, Battiwalla, Minoo, Baxter-Lowe, Lee Ann, Brunstein, Claudio, Chhabra, Saurabh, Perez, Miguel Angel Diaz, Fuchs, Ephraim J., Ganguly, Siddhartha, Hardy, Nancy, Hematti, Peiman, McGuirk, Joseph, Peres, Edward, Ringden, Olle, Rizzieri, David, Romee, Rizwan, Solh, Melhem, Szwajcer, David, van der Poel, Marjolein, Waller, Edmund, William, Basem M., and Eapen, Mary

Published
2020
Full Text
View/download PDF

21. Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study

Author

Durand, Christine M, Capoferri, Adam A, Redd, Andrew D, Zahurak, Marianna, Rosenbloom, Daniel I S, Cash, Ayla, Avery, Robin K, Bolaños-Meade, Javier, Bollard, Catherine M, Bullen, C Korin, Flexner, Charles, Fuchs, Ephraim J, Gallant, Joel, Gladstone, Doug E, Gocke, Christopher D, Jones, Richard J, Kasamon, Yvette L, Lai, Jun, Levis, Mark, Luznik, Leo, Marr, Kieren A, McHugh, Holly L, Mehta Steinke, Seema, Pham, Paul, Pohlmeyer, Christopher, Pratz, Keith, Shoham, Shmuel, Wagner-Johnston, Nina, Xu, Daniel, Siliciano, Janet D, Quinn, Thomas C, Siliciano, Robert F, and Ambinder, Richard F

Published
2020
Full Text
View/download PDF

22. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults

Author

Symons, Heather J., Zahurak, Marianna, Cao, Yilin, Chen, Allen, Cooke, Kenneth, Gamper, Christopher, Klein, Orly, Llosa, Nicolas, Zambidis, Elias T., Ambinder, Richard, Bolaños-Meade, Javier, Borrello, Ivan, Brodsky, Robert, DeZern, Amy, Gojo, Ivana, Showel, Margaret, Swinnen, Lode, Smith, B. Douglas, Luznik, Leo, Jones, Richard J., and Fuchs, Ephraim J.

Published
2020
Full Text
View/download PDF

24. Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014.

Author

Al Malki, Monzr, Horowitz, Mary, Handgretinger, Rupert, Leung, Wing, Roy, Denis-Claude, Huang, Xiao-Jun, Fuchs, Ephraim, Locatelli, Franco, Blaise, Didier, Mineishi, Shin, Martelli, Massimo, Miller, Jeffrey, June, Carl, Ai, Hui-Sheng, Luznik, Leo, Mavilio, Domenico, Lugli, Enrico, van den Brink, Marcel, Champlin, Richard, and Ciurea, Stefan

Subjects
Cellular therapy, Haploidentical transplantation, Immunologic reconstitution after transplantation, Post-transplantation cyclophosphamide, T cell depleted, Animals, Antineoplastic Agents, Alkylating, Clinical Trials as Topic, Cyclophosphamide, Disease Models, Animal, Graft vs Host Disease, HLA Antigens, Hematologic Neoplasms, Histocompatibility Testing, Humans, Mice, Recurrence, San Francisco, Secondary Prevention, Stem Cell Transplantation, Survival Analysis, T-Lymphocytes, Regulatory, Transplantation, Isogeneic, Unrelated Donors
Abstract

Significant progress has been made over the past decade in haploidentical transplantation, with the development of novel methods to control intense alloreactive reactions generated in the major HLA-mismatched setting. Application of post-transplantation cyclophosphamide has gained worldwide acceptance as an effective and low-cost way to perform this type of transplantation, with outcomes now similar to those from HLA-matched unrelated donors. These advances have resulted in improved treatment-related mortality, whereas disease relapse has emerged as the most common cause of treatment failure. In addition, improvements in immunologic reconstitution after transplantation are much needed, not only in haploidentical transplantation but in all forms of stem cell transplantation. This symposium has focused on some of the most promising methods to control alloreactivity in this form of transplantation and application of cellular therapy to prevent disease relapse after transplantation, as well as understanding immunologic reconstitution and foreseeable approaches to improve immune recovery after transplantation.

Published
2016

25. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Author

Boyiadzis, Michael, Bishop, Michael, Abonour, Rafat, Anderson, Kenneth, Ansell, Stephen, Avigan, David, Barbarotta, Lisa, Barrett, Austin, Van Besien, Koen, Bergsagel, P, Borrello, Ivan, Brody, Joshua, Brufsky, Jill, Cairo, Mitchell, Chari, Ajai, Cohen, Adam, Cortes, Jorge, Forman, Stephen, Friedberg, Jonathan, Fuchs, Ephraim, Gore, Steven, Jagannath, Sundar, Kahl, Brad, Kline, Justin, Kochenderfer, James, Kwak, Larry, Levy, Ronald, de Lima, Marcos, Litzow, Mark, Mahindra, Anuj, Miller, Jeffrey, Munshi, Nikhil, Orlowski, Robert, Pagel, John, Porter, David, Russell, Stephen, Schwartz, Karl, Shipp, Margaret, Siegel, David, Stone, Richard, Tallman, Martin, Timmerman, John, Van Rhee, Frits, Waller, Edmund, Welsh, Ann, Werner, Michael, Wiernik, Peter, and Dhodapkar, Madhav

Subjects
Acute leukemia, Cancer immunotherapy, Hematologic malignancies, Immunotherapy, Lymphoma, Multiple myeloma
Abstract

Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical responses. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consisting of physicians, nurses, patient advocates, and patients to develop consensus recommendations for the clinical application of immunotherapy for patients with multiple myeloma, lymphoma, and acute leukemia. These recommendations were developed following the previously established process based on the Institute of Medicines clinical practice guidelines. In doing so, a systematic literature search was performed for high-impact studies from 2004 to 2014 and was supplemented with further literature as identified by the panel. The consensus panel met in December of 2014 with the goal to generate consensus recommendations for the clinical use of immunotherapy in patients with hematologic malignancies. During this meeting, consensus panel voting along with discussion were used to rate and review the strength of the supporting evidence from the literature search. These consensus recommendations focus on issues related to patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Overall, immunotherapy is rapidly emerging as an effective therapeutic strategy for the management of hematologic malignances. Evidence-based consensus recommendations for its clinical application are provided and will be updated as the field evolves.

Published
2016

26. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source

Author

Sterling, Cole H., Hughes, Michael S., Tsai, Hua-Ling, Yarkony, Kathryn, Fuchs, Ephraim J., Swinnen, Lode J., Paul, Suman, Bolaños-Meade, Javier, Luznik, Leo, Imus, Philip H., Ali, Syed Abbas, Jain, Tania, Ambinder, Alexander, DeZern, Amy, Huff, Carol Ann, Gocke, Christian B., Varadhan, Ravi, Wagner-Johnston, Nina, Jones, Richard J., and Ambinder, Richard F.

Published
2023
Full Text
View/download PDF

28. Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years

Author

Webster, Jonathan A., Reed, Madison, Tsai, Hua-Ling, Ambinder, Alexander, Jain, Tania, Dezern, Amy E., Levis, Mark J., Showel, Margaret M., Prince, Gabrielle T., Hourigan, Christopher S., Gladstone, Douglas E., Bolanos-Meade, Javier, Gondek, Lukasz P., Ghiaur, Gabriel, Dalton, W. Brian, Paul, Suman, Fuchs, Ephraim J., Gocke, Christian B., Ali, Syed Abbas, Huff, Carol Ann, Borrello, Ivan M., Swinnen, Lode, Wagner-Johnston, Nina, Ambinder, Richard F., Luznik, Leo, Gojo, Ivana, Smith, B. Douglas, Varadhan, Ravi, Jones, Richard J., and Imus, Philip H.

Published
2023
Full Text
View/download PDF

29. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation

Author

Ciurea, Stefan O., Al Malki, Monzr M., Kongtim, Piyanuch, Fuchs, Ephraim J., Luznik, Leo, Huang, Xiao-Jun, Ciceri, Fabio, Locatelli, Franco, Aversa, Franco, Castagna, Luca, Bacigalupo, Andrea, Martelli, Massimo, Blaise, Didier, Ben Soussan, Patrick, Arnault, Yolande, Handgretinger, Rupert, Roy, Denis-Claude, O’Donnell, Paul V., Bashey, Asad, Solomon, Scott, Romee, Rizwan, Gayoso, Jorge, Lazarus, Hillard M., Ballen, Karen, Savani, Bipin N., Mohty, Mohamad, and Nagler, Arnon

Published
2020
Full Text
View/download PDF

32. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide–Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma

Author

Ahmed, Sairah, Kanakry, Jennifer A., Ahn, Kwang W., Litovich, Carlos, Abdel-Azim, Hisham, Aljurf, Mahmoud, Bacher, Vera Ulrike, Bejanyan, Nelli, Cohen, Jonathon B., Farooq, Umar, Fuchs, Ephraim J., Bolaños-Meade, Javier, Ghosh, Nilanjan, Herrera, Alex F., Hossain, Nasheed M., Inwards, David, Kanate, Abraham S., Martino, Rodrigo, Munshi, Pashna N., Murthy, Hemant, Mussetti, Alberto, Nieto, Yago, Perales, Miguel-Angel, Romee, Rizwan, Savani, Bipin N., Seo, Sachiko, Wirk, Baldeep, Yared, Jean A., Sureda, Ana, Fenske, Timothy S., and Hamadani, Mehdi

Published
2019
Full Text
View/download PDF

33. Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide

Author

McCurdy, Shannon R., Kanakry, Christopher G., Tsai, Hua-Ling, Gojo, Ivana, Smith, B. Douglas, Gladstone, Douglas E., Bolaños-Meade, Javier, Borrello, Ivan, Matsui, William H., Swinnen, Lode J., Huff, Carol Ann, Brodsky, Robert A., Ambinder, Richard F., Fuchs, Ephraim J., Rosner, Gary L., Jones, Richard J., and Luznik, Leo

Published
2019
Full Text
View/download PDF

34. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial

Author

Bolaños-Meade, Javier, Cooke, Kenneth R, Gamper, Christopher J, Ali, Syed Abbas, Ambinder, Richard F, Borrello, Ivan M, Fuchs, Ephraim J, Gladstone, Douglas E, Gocke, Christian B, Huff, Carol Ann, Luznik, Leo, Swinnen, Lode J, Symons, Heather J, Terezakis, Stephanie A, Wagner-Johnston, Nina, Jones, Richard J, and Brodsky, Robert A

Published
2019
Full Text
View/download PDF

35. Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes

Author

McCurdy, Shannon R., Muth, Stephen T., Tsai, Hua-Ling, Symons, Heather J., Huff, Carol Ann, Matsui, William H., Borrello, Ivan, Gladstone, Douglas E., Swinnen, Lode J., Cooke, Kenneth R., Brodsky, Robert A., Bolaños-Meade, Javier, Ambinder, Richard F., Varadhan, Ravi, Luznik, Leo, Jones, Richard J., Bettinot, Maria P., and Fuchs, Ephraim J.

Published
2018
Full Text
View/download PDF

36. Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012

Author

Brunstein, Claudio G., O'Donnell, Paul V., Logan, Brent, Dawson, Peter, Costa, Luciano, Cutler, Corey, Craig, Michael, Hogan, William, Horowitz, Mary M., Horwitz, Mitchell E., Karanes, Chatchada, Magenau, John M., Malone, Adriana, McCarty, John, McGuirk, Joseph P., Morris, Lawrence E., Rezvani, Andrew R., Salit, Rachel, Vasu, Sumithira, Eapen, Mary, and Fuchs, Ephraim J.

Published
2022
Full Text
View/download PDF

37. Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis

Author

Jain, Tania, Tsai, Hua-Ling, DeZern, Amy E., Gondek, Lukasz P., Elmariah, Hany, Bolaños-Meade, Javier, Luznik, Leonido, Fuchs, Ephraim, Ambinder, Richard, Gladstone, Douglas E., Imus, Philip, Webster, Jonathan, Prince, Gabrielle, Ghiaur, Gabriel, Smith, B. Douglas, Ali, Syed Abbas, Ambinder, Alexander, Dalton, William B., Gocke, Christian B., Huff, Carol Ann, Gojo, Ivana, Swinnen, Lode, Wagner-Johnston, Nina, Borrello, Ivan, Varadhan, Ravi, Levis, Mark, and Jones, Richard J.

Published
2022
Full Text
View/download PDF

42. Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide

Author

McCurdy, Shannon R., Kanakry, Christopher G., Tsai, Hua-Ling, Kasamon, Yvette L., Showel, Margaret M., Bolaños-Meade, Javier, Huff, Carol Ann, Borrello, Ivan, Matsui, William H., Brodsky, Robert A., Ambinder, Richard F., Bettinotti, Maria P., Fuchs, Ephraim J., Rosner, Gary L., Jones, Richard J., and Luznik, Leo

Published
2018
Full Text
View/download PDF

43. Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes

Author

O'Donnell, Paul V., Brunstein, Claudio G., Fuchs, Ephraim J., Zhang, Mei-Jie, Allbee-Johnson, Mariam, Antin, Joseph H., Leifer, Eric S., Elmariah, Hany, Grunwald, Michael R., Hashmi, Hamza, Horowitz, Mary M., Magenau, John M., Majhail, Navneet, Milano, Filippo, Morris, Lawrence E., Rezvani, Andrew R., McGuirk, Joseph P., Jones, Richard J., and Eapen, Mary

Published
2022
Full Text
View/download PDF

44. Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients

Author

Llosa, Nicolas J., Cooke, Kenneth R., Chen, Allen R., Gamper, Christopher J., Klein, Orly R., Zambidis, Elias T., Luber, Brandon, Rosner, Gary, Siegel, Nicholas, Holuba, Mary Jo, Robey, Nancy, Hayashi, Masanori, Jones, Richard J., Fuchs, Ephraim, Holdhoff, Matthias, Loeb, David M., and Symons, Heather J.

Published
2017
Full Text
View/download PDF

46. Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation

Author

Imus, Philip H., Blackford, Amanda L., Bettinotti, Maria, Iglehart, Brian, Dietrich, August, Tucker, Noah, Symons, Heather, Cooke, Kenneth R., Luznik, Leo, Fuchs, Ephraim J., Brodsky, Robert A., Matsui, William H., Huff, Carol Ann, Gladstone, Douglas, Ambinder, Richard F., Borrello, Ivan M., Swinnen, Lode J., Jones, Richard J., and Bolaños-Meade, Javier

Published
2017
Full Text
View/download PDF

47. Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Author

DeZern, Amy, primary, Zahurak, Marianna L, additional, Symons, Heather J, additional, Cooke, Kenneth R., additional, Huff, Carol Ann, additional, Jain, Tania, additional, Swinnen, Lode J, additional, Imus, Philip Hollingsworth, additional, Wagner-Johnston, Nina D., additional, Ambinder, Richard F, additional, Levis, Mark J., additional, Luznik, Leo, additional, Bolaños-Meade, Javier, additional, Fuchs, Ephraim J, additional, Jones, Richard J, additional, and Brodsky, Robert A., additional

Published
2023
Full Text
View/download PDF

48. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Author

Luznik, Leo, O'Donnell, Paul V, Symons, Heather J, Chen, Allen R, Leffell, M Susan, Zahurak, Marianna, Gooley, Ted A, Piantadosi, Steve, Kaup, Michele, Ambinder, Richard F, Huff, Carol Ann, Matsui, William, Bolaños-Meade, Javier, Borrello, Ivan, Powell, Jonathan D, Harrington, Elizabeth, Warnock, Sandy, Flowers, Mary, Brodsky, Robert A, Sandmaier, Brenda M, Storb, Rainer F, Jones, Richard J, and Fuchs, Ephraim J

Subjects
Humans, Hematologic Neoplasms, Hemoglobinuria, Paroxysmal, Graft vs Host Disease, Postoperative Complications, Mycophenolic Acid, Cyclophosphamide, Tacrolimus, Filgrastim, Granulocyte Colony-Stimulating Factor, Recombinant Proteins, Vidarabine, Immunosuppressive Agents, Disease-Free Survival, Blood Component Transfusion, Transplantation Conditioning, Postoperative Care, Whole-Body Irradiation, Bone Marrow Transplantation, Transplantation, Homologous, Drug Administration Schedule, Histocompatibility, Graft Survival, Adult, Aged, Middle Aged, Female, Male, bone marrow transplantation, cyclophosphamide, histocompatibility antigens, conditioning regimens, leukemia, lymphoma, Hemoglobinuria, Paroxysmal, Transplantation, Homologous, Immunology, Clinical Sciences
Abstract

We evaluated the safety and efficacy of high-dose, posttransplantation cyclophosphamide (Cy) to prevent graft rejection and graft-versus-host disease (GVHD) after outpatient nonmyeloablative conditioning and T cell-replete bone marrow transplantation from partially HLA-mismatched (haploidentical) related donors. Patients with advanced hematologic malignancies (n = 67) or paroxysmal nocturnal hemoglobinuria (n = 1) received Cy 50 mg/kg i.v. on day 3 (n = 28) or on days 3 and 4 (n = 40) after transplantation. The median times to neutrophil (>500/microL) and platelet recovery (>20,000/microL) were 15 and 24 days, respectively. Graft failure occurred in 9 of 66 (13%) evaluable patients, and was fatal in 1. The cumulative incidences of grades II-IV and grades III-IV acute (aGVHD) by day 200 were 34% and 6%, respectively. There was a trend toward a lower risk of extensive chronic GVHD (cGVHD) among recipients of 2 versus 1 dose of posttransplantation Cy (P = .05), the only difference between these groups. The cumulative incidences of nonrelapse mortality (NRM) and relapse at 1 year were 15% and 51%, respectively. Actuarial overall survival (OS) and event-free survival (EFS) at 2 years after transplantation were 36% and 26%, respectively. Patients with lymphoid malignancies had an improved EFS compared to those with myelogenous malignancies (P = .02). Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD.

Published
2008

49. Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide

Author

Rappazzo, Katherine C., Zahurak, Marianna, Bettinotti, Maria, Ali, Syed Abbas, Ambinder, Alex J., Bolaños-Meade, Javier, Borrello, Ivan, Dezern, Amy E., Gladstone, Doug, Gocke, Christian, Fuchs, Ephraim, Huff, Carol Ann, Imus, Philip H., Jain, Tania, Luznik, Leo, Rahmat, Leena, Swinnen, Lode J., Wagner-Johnston, Nina, Jones, Richard J., and Ambinder, Richard F.

Published
2021
Full Text
View/download PDF

50. Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma

Author

Sterling, Cole H., Tsai, Hua-Ling, Holdhoff, Matthias, Bolaños-Meade, Javier, Luznik, Leo, Fuchs, Ephraim J., Huff, Carol Ann, Gocke, Christian B., Ali, Syed Abbas, Borrello, Ivan M., Varadhan, Ravi, Jones, Richard J., Gladstone, Douglas E., Ambinder, Richard F., Wagner-Johnston, Nina, Swinnen, Lode J., and Imus, Philip H.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results